171567-86-5

Basic information

• Product Name: MOC-D-Valine
• Synonyms: MOC-D-Valine;(2R)-2-(methoxycarbonylamino)-3-methylbutanoic acid;(R)-2-(Methoxycarbonylamino)-3-methylbutanoic acid;(R)-2-((Methoxycarbonyl)aMino)-4-Methylbutanoic acid;(R)-(+)-N-(Methoxycarbonyl)valine;Methoxycarbonyl-D-Valine;N-METHOXYCARBONYL-D-VALINE
• CAS NO: 171567-86-5
• Molecular Formula: C₇H₁₃NO₄
• Molecular Weight: 175.18242
• Mol File: 171567-86-5.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 315.9±25.0 °C(Predicted)
• Appearance: /
• Density: 1.154±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 4.44±0.10(Predicted)
• CAS DataBase Reference: MOC-D-Valine(CAS DataBase Reference)
• NIST Chemistry Reference: MOC-D-Valine(171567-86-5)
• EPA Substance Registry System: MOC-D-Valine(171567-86-5)

Safety Data

• Hazardous Substances Data: 171567-86-5(Hazardous Substances Data)

Usage

Description

MOC-D-Valine, also known as (R)-2-((Methoxycarbonyl)amino)-3-methylbutanoic Acid, is an organic compound that plays a significant role in the pharmaceutical industry. It is a derivative of amino acids, characterized by its unique chemical structure that includes a methoxycarbonyl group and a methyl group. MOC-D-Valine is known for its potential applications in the development of therapeutic agents and synthetic chemistry.

Uses

Used in Pharmaceutical Industry:
MOC-D-Valine is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows it to be a valuable building block for the development of new drugs with specific therapeutic properties.
Used in Antiviral Applications:
MOC-D-Valine is used as a synthetic precursor for the preparation of dipeptide-capped bis-phenylimidazole derivatives. These derivatives have been identified as inhibitors of the hepatitis C virus NS5A replication complex, making MOC-D-Valine an essential component in the development of antiviral treatments against hepatitis C.

Upstream product

• 640-68-6 D-Val-OH 
• 79-22-1 methyl chloroformate 

Downstream Products

• 1512624-39-3 dimethyl (2R,2'R)-1,1'-((2S,2'S)-2,2'-(biphenyl-4,4'-diylbis(azandiyl))bis(oxomethylene)bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl)dicarbamate 
• 1447740-82-0 C₄₀H₅₂N₆O₈ 
• 1228668-60-7 C₃₉H₅₃F₂N₉O₆ 
• 1312608-55-1 C₄₄H₅₂N₈O₆ 
• 1310695-52-3 C₄₀H₄₈N₆O₆S₂ 

Relevant articles and documents

Redesigning of the cap conformation and symmetry of the diphenylethyne core to yield highly potent pan-genotypic NS5A inhibitors with high potency and high resistance barrier

Herein, we report the discovery of several NS5A inhibitors with potency against HCV genotype 1b in the picomolar range. Compounds (15, 33) were of extremely high potency against HCV genotype 1b (EC50 ≈ 1 pM), improved activity against genotype 3a (GT 3a) and good metabolic stability. We studied the impact of changing the cap conformation relative to the diphenylethyne core and/or compound symmetry on both potency and metabolic stability. The analogs obtained exhibited improved potency against HCV genotypes 1a, 1b, 3a and 4a compared to the clinically approved candidate daclatasvir with EC50 values in the low picomolar range and SI50s > 7 orders of magnitude. Compound 15, a symmetrically m-, m’-substituted diphenyl ethyne analog, was 150-fold more potent than daclatasvir against GT 3a, while compound 33, an asymmetrically m-, p-substituted diphenyl ethyne analog, was 35-fold more potent than daclatasvir against GT 3a. In addition, compound 15 exhibited a higher resistance barrier than daclatasvir against genotype 1b.

Sulfur(vi) fluoride exchange as a key reaction for synthesizing biaryl sulfate core derivatives as potent hepatitis C virus NS5A inhibitors and their structure-activity relationship studies

Extremely potent, new hepatitis C virus (HCV) nonstructural 5A (NS5A) featuring substituted biaryl sulfate core structures was designed and synthesized. Based on the previously reported novel HCV NS5A inhibitors featuring biaryl sulfate core structures which exhibit two-digit picomolar half-maximal effective concentration (EC50) values against HCV genotype 1b and 2a, the new inhibitors equipped with the sulfate core structures containing diversely substituted aryl groups were explored. In this study, highly efficient, chemoselective coupling reactions between an arylsulfonyl fluoride and an aryl silyl ether, known as the sulfur(vi) fluoride exchange (SuFEx) reaction, were utilized. Among the inhibitors prepared based on the SuFEx chemistry, compounds 14, 15 and 29 exhibited two-digit picomolar EC50 values against GT-1b and single digit or sub nanomolar activities against the HCV GT-2a strain. Nonsymmetrical inhibitors containing an imidazole and amide moieties on each side of the sulfate core structures were also synthesized. In addition, a biotinylated probe targeting NS5A protein was prepared for labeling using the same synthetic methodology.

Diphenyl sulfate derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and pharmaceutical composition for use in preventing or treating hepatitis C virus related diseases

The present invention relates to a diphenyl sulfate derivative or a pharmaceutically acceptable salt thereof, a production method thereof, and a pharmaceutical composition for preventing or treating hepatitis C virus-associated diseases containing the same as an active ingredient. According to the present invention, the diphenyl sulfate derivative excellently inhibits infection by hepatitis C virus and replication of hepatitis C virus, and thus can be useful as pharmaceutical compositions for preventing or treating liver diseases such as hepatocellular cancer, cirrhosis, chronic hepatitis C, and acute hepatitis C caused by hepatitis C virus.COPYRIGHT KIPO 2017